Ekspresi 17Β-Hydroxysteroid Dehidrogenase (17bhsd) Tipe 2 Pada Jaringan Endometriosis
DAFTAR PUSTAKA
1. Baziad A. Endometriosis. Endokrinologi Ginekologi. Media Aesculapius
Fakultas Kedokteran Universitas Indonesia 2008.
2. Astarto NW, Djuwanto T, Permadi W, Madjid TH, Bayuaji H, Ritonga
MA. Apakah endometriosis mengganggu fungsi endometrium normal?.
Kupas Tuntas Kelainan Haid. Fakultas Kedokteran Universitas
Padjajaran 2011.
3. Djuwantono T, Bayuaji H, Permadi W. Bagaimana kita yakin itu
endometriosis?. Penanganan Kelainan Endokrinologi Reproduksi dan
Fertilitas dalam praktek sehari-hari. Fakultas Kedokteran Universitas
Padjajaran 2012.
4. Sourial S, Tempest N, Hapangama DK. Theories on the pathogenesis
of endometriosis. International Journal of Reproductive Medicine 2014.
5. Bulun SE. Mechanisms of disease endometriosis. The New England
Journal of Medicine 2009;360(3):268-79.
6. Siregar HS. L-selectin P213S polymorphism and macrophage profils in
endometriosis; an new insight into the pathofisiology of endometriosis.
Lambert Academic Publishing 2014.
7. Burney RO, Giudice LC. Pathogenesis and pathophysiology of
endometriosis. Fertility and Sterility 2012.
46
8. Zeitoun K. Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson
S, et al. Deficient 17β-hydroxysteroid dehydrogenase type 2
expression in endometriosis: failure to metabolize 17β-estradiol.
Journal of Clinical Endocrinology and Metabolism 1998;83(12):447480.
9. Burton KA, Henderson TA, Hillier SG, Mason JI, Habib F, Brenner RM,
et al. Local levonogestrel regulation of androgen receptor and 17βhydroxysteroid
endometrium.
dehydrogenase
European
type
Society
of
2
expression
Human
in
human
Reproduction
and
Embryology 2003;18(12):2610-17.
10. Husen B, Psonka N, Meisel MJ, Keil C, Rune GM. Differential
expression of 17β-hydroxysteroid dehydrogenase type 2 and 4 in
human endometrial epithelial cell
lines.
Journal of
Molecular
Endocrinology 2000;24:135-44.
11. Miettinen MM, Mustonen MVJ, Poutanen MH, Isomaa VV, Vihko R.
Human 17β-hydroxysteroid dehydrogenase type 1 and type 2
isoenzymes have opposite activities in cultured cells and characteristic
cell and tissue specific expression. Biochem. J. 1996;314:839-45.
12. Carneiro MM, Morsch DM, Camargos AF, Spritzer PM, Reis FM.
Expression of 17β-hydroxysteroid dehydrogenase type 2 in pelvic
endometriosis. Gynecological Endocrinology 2007;23(4):188-92.
47
13. Cristescu C, Veliscu A, Marinescu B, Patrascu A, Tranca ET, Pop OT.
Endometriosis clinical approach based on histological findings.
Romanian Journal of Morphology & Embryology 2013;54(1):91-7.
14. Velasco I, Rueda J, Acien P. Aromatase expression in endometriotic
tissues and cell cultures of patients with endometriosis 2006;12(6):37781.
15. Bulun SE, Cheng YH, Pavone ME, Xue Q, Attar E, Trukhacheva E, et
al. estrogen receptor-β, estrogen receptor-α, and progesterone
resistance in endometriosis. Semin Reprod Med 2010;28(1):36-43.
16. Ilie R, Ilie I. The Implication of Angiogenesis in Endometriosis.
Biotechnology Molecular Biology and Nanomedicine 2014;2(1):5-12.
17. Leyland N, Casper R, Laberge P, Singh SS. Endometriosis: diagnosis
and management. Journal of Obstetrics abd Gynaecology Canada
2010;32(7):1-35.
18. Endometriosis
A
Guide
for
Patients.
American
Society
for
Reproductive Medicine 2012.
19. Schorge JO, Schaffer JI, Halvorson LM, Hoffman B, Bradshaw KD,
Cunningham FG. Endometriosis. Williams Gynecology 2008.
20. Suresh PS, Venkatesh T, Rajan T, Tsutsumi R. Molecular pathology
and therapy of endometrriosis. Andrology and Gynecology Current
Research 2013;1:1-13.
48
21. Bulun SE, Zeitoun K, Takayama K, Noble L, Michael D, Simpson E, et
al. Estrogen production in endometriosis and use of aromatase
inhibitors
to
treat
endometriosis.
Endocrine-Related
Cancer
1999;6:293-301.
22. Guideline of the European Society of Human Reproduction and
Embryology. Management of women with endometriosis. ESHRE
Endometriosis Guideline Development Group 2013.
23. Vigano P, Rabellotti E, Pagliardini L, Somigliana E, Candiani M,
Vercellini P. progesterone resistance, aromatase, and inflammation:
the important relationships between hormones and inflammation. Curr
obstet Gynecol Rep 2012;1:146-52.
24. Pullen N. progesterone resistance and targeting the progesterone
receptors: a therapeutic approach to endometriosis 2012:157-82.
25. Huhtinen
K.
Molecular
prifiling
of
human
endometrium
and
endometriosis. University of Turku 2010.
26. Miettinen M. 17β hydroxysteroid dehydrogenase types 1 and 2. Oulu
University Library 1999.
27. Rantakari P. the role of hydroxysteroid (17-beta) dehydrogenases 2,7,
and 12 in mouse development. University of Turku 2010.
28. Dunselman GAJ, Vermeulen N, Becker C, Jorge CC, Hooghe TD, Bie
BD,
et
al.
ESHRE
guideline:
management
of
women
with
endometriosis. Human Reproduction 2014;29(3):400-12.
49
29. Fadhlaoui A, Joliniere JB, Feki A. Endometriosis and infertility how and
when to treat. Frontiers in surgery 2014;1(24)1-6.
30. Fernandez EO, Ossadey CF. Clinical management of endometriosis
from mild to severe. Global Congress on Minimally Invasive
Gynecology 2013.
31. Bhaskaran
SS,
Nair
HB.
Progestins/antiprogestins:
role
in
pathogenesis and treatment for endometriosis. Gynecol Obstet
2012;2(3):1-2.
32. Descamps P, Andreeva E, Leng J, Salehpour S, Chapron C. The place
of gonadotropin-releasing hormone agonists in the management of
endometriosis. Journal of Endometriosis and Pelvic Pain Disorders
2014:1-11.
33. Faienza MF, Cavallo L. 17β-hydroxysteroid dehydrogenase type 3
deficiency: diagnosis, phenotypic variability and molecular findings.
Department of Biomedicine of Developmental Age, University of Bari,
Italy 2012.
34. Peltoketo H, Luu-Tse V, Simard J, Adamski J. 17β-hydroxysteroid
dehydrogenase (HSD) / 17-ketosteroid reductase (KSR) family;
nomenclature and main characteristics of the 17HSD/KSR enzymes.
Journal of Molecular Endocrinology 1999;23:1-11.
35. Labrie F, Tse VL, Lin SX, Simard J, Labrie C, Alfy ME. Intracrinology:
role of the family of 17β-hydroxysteroid dehydrogenase in human
50
physiology
and
disease.
Journal
of
Molecular
Endocrinology
2000;25:1-16.
36. Bulun SE, Cheng YH, Pavone ME, Yin P, Imir G, Utsunomiya H, et al.
17β-hydroxysteroid
dehydrogenase
type
2
deficiency
and
progesterone resistance in endometriosis. Semin. Reprod. Med.
2010;28:44-50.
37. Cheng YH, Yin P, Xue Q, Yilmaz B, Dawson MI, Bulun SE. Retinoic
acid (RA) regulates 17β-hydroxysteroid dehydrogenase type 2
expression in endometrium: interaction of RA receptors with specificity
protein (SP) 1/SP3 for estradiol metabolism. J. Clin. Endocrinol. Metab.
2008;93(5):1915-23.
38. Matsuzaki S, Canis M, Pouly JL, Dechelotte PJ, Mage G. analysis of
aromatase and 17β-hydroxysteroid dehydrogenase type 2 messenger
ribonucleic acid expression in deep endometriosis and eutopic
endometrium using laser capture microdissection. Fertility and Sterility
2006;85(2):308-13.
39. Bulun SE, Zeitoun KM, Takayama K, Sasano H. Estrogen biosynthesis
in endometriosis: molecular basis and clinical relevance. Journal of
Molecular Endocrinology 2000;25:35-42.
40. Dassen H, Punyadeera, Kamps R, Delvoux B, Langendonckt AV.
Donnez J, et al. Estrogen metabolizing enzymes in endometrium and
endometriosis. Human Reproduction 2007;22(12):3148-58.
51
41. Casey
ML,
Macdonald
PC,
Andersson
S.
17β-hydroxysteroid
dehydrogenase type 2: chromosomal assignment and progestin
regulation of gene expression in human endometrium.
42. Cheng YH. Imir A, Suzuki T, Fenkci V, Yilmaz B, Sasano H, et al. sp1
and sp3 mediate progesterone-dependent induction of the 17beta
hydroxysteroid dehydrogenase type 2 gene in human endometrium.
Biology of Reproduction 2006;75:605-14.
43. Agarwal A. Role of oxidative stress in endometriosis. Reproductive
Biomedicine Online 2006;13(1):126-34.
44. Meiling H, Lingya PL, Baozhen W. A case control epidemiologic study
of endometriosis. Chinese Medical Science Journal 1994;9:114-8.
52
1. Baziad A. Endometriosis. Endokrinologi Ginekologi. Media Aesculapius
Fakultas Kedokteran Universitas Indonesia 2008.
2. Astarto NW, Djuwanto T, Permadi W, Madjid TH, Bayuaji H, Ritonga
MA. Apakah endometriosis mengganggu fungsi endometrium normal?.
Kupas Tuntas Kelainan Haid. Fakultas Kedokteran Universitas
Padjajaran 2011.
3. Djuwantono T, Bayuaji H, Permadi W. Bagaimana kita yakin itu
endometriosis?. Penanganan Kelainan Endokrinologi Reproduksi dan
Fertilitas dalam praktek sehari-hari. Fakultas Kedokteran Universitas
Padjajaran 2012.
4. Sourial S, Tempest N, Hapangama DK. Theories on the pathogenesis
of endometriosis. International Journal of Reproductive Medicine 2014.
5. Bulun SE. Mechanisms of disease endometriosis. The New England
Journal of Medicine 2009;360(3):268-79.
6. Siregar HS. L-selectin P213S polymorphism and macrophage profils in
endometriosis; an new insight into the pathofisiology of endometriosis.
Lambert Academic Publishing 2014.
7. Burney RO, Giudice LC. Pathogenesis and pathophysiology of
endometriosis. Fertility and Sterility 2012.
46
8. Zeitoun K. Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson
S, et al. Deficient 17β-hydroxysteroid dehydrogenase type 2
expression in endometriosis: failure to metabolize 17β-estradiol.
Journal of Clinical Endocrinology and Metabolism 1998;83(12):447480.
9. Burton KA, Henderson TA, Hillier SG, Mason JI, Habib F, Brenner RM,
et al. Local levonogestrel regulation of androgen receptor and 17βhydroxysteroid
endometrium.
dehydrogenase
European
type
Society
of
2
expression
Human
in
human
Reproduction
and
Embryology 2003;18(12):2610-17.
10. Husen B, Psonka N, Meisel MJ, Keil C, Rune GM. Differential
expression of 17β-hydroxysteroid dehydrogenase type 2 and 4 in
human endometrial epithelial cell
lines.
Journal of
Molecular
Endocrinology 2000;24:135-44.
11. Miettinen MM, Mustonen MVJ, Poutanen MH, Isomaa VV, Vihko R.
Human 17β-hydroxysteroid dehydrogenase type 1 and type 2
isoenzymes have opposite activities in cultured cells and characteristic
cell and tissue specific expression. Biochem. J. 1996;314:839-45.
12. Carneiro MM, Morsch DM, Camargos AF, Spritzer PM, Reis FM.
Expression of 17β-hydroxysteroid dehydrogenase type 2 in pelvic
endometriosis. Gynecological Endocrinology 2007;23(4):188-92.
47
13. Cristescu C, Veliscu A, Marinescu B, Patrascu A, Tranca ET, Pop OT.
Endometriosis clinical approach based on histological findings.
Romanian Journal of Morphology & Embryology 2013;54(1):91-7.
14. Velasco I, Rueda J, Acien P. Aromatase expression in endometriotic
tissues and cell cultures of patients with endometriosis 2006;12(6):37781.
15. Bulun SE, Cheng YH, Pavone ME, Xue Q, Attar E, Trukhacheva E, et
al. estrogen receptor-β, estrogen receptor-α, and progesterone
resistance in endometriosis. Semin Reprod Med 2010;28(1):36-43.
16. Ilie R, Ilie I. The Implication of Angiogenesis in Endometriosis.
Biotechnology Molecular Biology and Nanomedicine 2014;2(1):5-12.
17. Leyland N, Casper R, Laberge P, Singh SS. Endometriosis: diagnosis
and management. Journal of Obstetrics abd Gynaecology Canada
2010;32(7):1-35.
18. Endometriosis
A
Guide
for
Patients.
American
Society
for
Reproductive Medicine 2012.
19. Schorge JO, Schaffer JI, Halvorson LM, Hoffman B, Bradshaw KD,
Cunningham FG. Endometriosis. Williams Gynecology 2008.
20. Suresh PS, Venkatesh T, Rajan T, Tsutsumi R. Molecular pathology
and therapy of endometrriosis. Andrology and Gynecology Current
Research 2013;1:1-13.
48
21. Bulun SE, Zeitoun K, Takayama K, Noble L, Michael D, Simpson E, et
al. Estrogen production in endometriosis and use of aromatase
inhibitors
to
treat
endometriosis.
Endocrine-Related
Cancer
1999;6:293-301.
22. Guideline of the European Society of Human Reproduction and
Embryology. Management of women with endometriosis. ESHRE
Endometriosis Guideline Development Group 2013.
23. Vigano P, Rabellotti E, Pagliardini L, Somigliana E, Candiani M,
Vercellini P. progesterone resistance, aromatase, and inflammation:
the important relationships between hormones and inflammation. Curr
obstet Gynecol Rep 2012;1:146-52.
24. Pullen N. progesterone resistance and targeting the progesterone
receptors: a therapeutic approach to endometriosis 2012:157-82.
25. Huhtinen
K.
Molecular
prifiling
of
human
endometrium
and
endometriosis. University of Turku 2010.
26. Miettinen M. 17β hydroxysteroid dehydrogenase types 1 and 2. Oulu
University Library 1999.
27. Rantakari P. the role of hydroxysteroid (17-beta) dehydrogenases 2,7,
and 12 in mouse development. University of Turku 2010.
28. Dunselman GAJ, Vermeulen N, Becker C, Jorge CC, Hooghe TD, Bie
BD,
et
al.
ESHRE
guideline:
management
of
women
with
endometriosis. Human Reproduction 2014;29(3):400-12.
49
29. Fadhlaoui A, Joliniere JB, Feki A. Endometriosis and infertility how and
when to treat. Frontiers in surgery 2014;1(24)1-6.
30. Fernandez EO, Ossadey CF. Clinical management of endometriosis
from mild to severe. Global Congress on Minimally Invasive
Gynecology 2013.
31. Bhaskaran
SS,
Nair
HB.
Progestins/antiprogestins:
role
in
pathogenesis and treatment for endometriosis. Gynecol Obstet
2012;2(3):1-2.
32. Descamps P, Andreeva E, Leng J, Salehpour S, Chapron C. The place
of gonadotropin-releasing hormone agonists in the management of
endometriosis. Journal of Endometriosis and Pelvic Pain Disorders
2014:1-11.
33. Faienza MF, Cavallo L. 17β-hydroxysteroid dehydrogenase type 3
deficiency: diagnosis, phenotypic variability and molecular findings.
Department of Biomedicine of Developmental Age, University of Bari,
Italy 2012.
34. Peltoketo H, Luu-Tse V, Simard J, Adamski J. 17β-hydroxysteroid
dehydrogenase (HSD) / 17-ketosteroid reductase (KSR) family;
nomenclature and main characteristics of the 17HSD/KSR enzymes.
Journal of Molecular Endocrinology 1999;23:1-11.
35. Labrie F, Tse VL, Lin SX, Simard J, Labrie C, Alfy ME. Intracrinology:
role of the family of 17β-hydroxysteroid dehydrogenase in human
50
physiology
and
disease.
Journal
of
Molecular
Endocrinology
2000;25:1-16.
36. Bulun SE, Cheng YH, Pavone ME, Yin P, Imir G, Utsunomiya H, et al.
17β-hydroxysteroid
dehydrogenase
type
2
deficiency
and
progesterone resistance in endometriosis. Semin. Reprod. Med.
2010;28:44-50.
37. Cheng YH, Yin P, Xue Q, Yilmaz B, Dawson MI, Bulun SE. Retinoic
acid (RA) regulates 17β-hydroxysteroid dehydrogenase type 2
expression in endometrium: interaction of RA receptors with specificity
protein (SP) 1/SP3 for estradiol metabolism. J. Clin. Endocrinol. Metab.
2008;93(5):1915-23.
38. Matsuzaki S, Canis M, Pouly JL, Dechelotte PJ, Mage G. analysis of
aromatase and 17β-hydroxysteroid dehydrogenase type 2 messenger
ribonucleic acid expression in deep endometriosis and eutopic
endometrium using laser capture microdissection. Fertility and Sterility
2006;85(2):308-13.
39. Bulun SE, Zeitoun KM, Takayama K, Sasano H. Estrogen biosynthesis
in endometriosis: molecular basis and clinical relevance. Journal of
Molecular Endocrinology 2000;25:35-42.
40. Dassen H, Punyadeera, Kamps R, Delvoux B, Langendonckt AV.
Donnez J, et al. Estrogen metabolizing enzymes in endometrium and
endometriosis. Human Reproduction 2007;22(12):3148-58.
51
41. Casey
ML,
Macdonald
PC,
Andersson
S.
17β-hydroxysteroid
dehydrogenase type 2: chromosomal assignment and progestin
regulation of gene expression in human endometrium.
42. Cheng YH. Imir A, Suzuki T, Fenkci V, Yilmaz B, Sasano H, et al. sp1
and sp3 mediate progesterone-dependent induction of the 17beta
hydroxysteroid dehydrogenase type 2 gene in human endometrium.
Biology of Reproduction 2006;75:605-14.
43. Agarwal A. Role of oxidative stress in endometriosis. Reproductive
Biomedicine Online 2006;13(1):126-34.
44. Meiling H, Lingya PL, Baozhen W. A case control epidemiologic study
of endometriosis. Chinese Medical Science Journal 1994;9:114-8.
52